Munich-based Wacker reports that it is investing in its production facilities for live microbial products and vaccines at its Amsterdam site. The projects include the construction of a new fermentation line with a volume of 1,500 liters as well as creating new cleanroom structures in the 270-liter fermentation line. The investment price is a mid-double-digit million-euro amount, according to the company.

“By investing in new plants and production equipment, we are continuing to upgrade the Amsterdam site two years after Wacker took it over, and are making our company fit for the future,” explained Jörg Lindemann, PhD, managing director of the Wacker subsidiary Wacker Biotech.

The new construction projects will contribute to preparing the plant to produce new classes of pDNA and mRNA-based vaccines, added Lindemann. These nucleic acid-based actives are currently playing a role, for example, in the search for a vaccine against the new SARS-CoV-2 coronavirus.

As a CDMO, Wacker Biotech combines the Wacker Group’s biopharmaceutical activities. Wacker took over the Amsterdam site in 2018, doubling the company’s biologics capacity. Services also are provided by a fill-and-finish facility for filling and lyophilization, which enables the complete manufacture of pharmaceuticals from the active agent to the filled product, continued Lindemann.

Previous articlefMRIs Show Mental Fatigue’s Impact on MS Patients’ Cognitive Cerebral Responses
Next articleMassachusetts Biopharma Industry Weathers COVID-19 Impacts on Jobs, Financing